By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous anxiolytics, sedatives and hypnotics > Eszopiclone > Eszopiclone Dosage
Miscellaneous anxiolytics, sedatives and hypnotics
https://themeditary.com/dosage-information/eszopiclone-dosage-385.html

Eszopiclone Dosage

Drug Detail:Eszopiclone (Eszopiclone [ e-zop-i-klone ])

Drug Class: Miscellaneous anxiolytics, sedatives and hypnotics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Insomnia

Initial dose: 1 mg orally once a day immediately before bedtime
Maintenance dose: 1 to 3 mg orally once a day immediately before bedtime
Maximum dose: 3 mg/day

Comments:

  • The lowest effective dose should be used.
  • Patients should be monitored for cognitive and/or motor impairments, especially if this drug is used repeatedly.
  • Patients should be reevaluated if insomnia persists after 7 to 10 days of treatment.

Use: Treatment of insomnia

Usual Geriatric Dose for Insomnia

Initial dose: 1 mg orally once a day immediately before bedtime
Maintenance dose: 1 to 2 mg orally once a day immediately before bedtime
Maximum dose: 2 mg/day

Comments:

  • The lowest effective dose should be used.
  • Patients should be monitored for cognitive and/or motor impairments, especially if this drug is used repeatedly.
  • Patients should be reevaluated if insomnia persists after 7 to 10 days of treatment.

Use: Treatment of insomnia

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended; use with caution.
Severe liver dysfunction: Up to 2 mg orally once a day immediately prior to bedtime

  • Maximum dose: 2 mg/day

Dose Adjustments

CONCOMITANT USE WITH CENTRAL NERVOUS SYSTEM (CNS) DEPRESSANTS: Dose adjustment may be required; however, no specific guidelines have been suggested. Caution is recommended.

DEBILITATED PATIENTS AND/OR THOSE TAKING POTENT CYP450 3A4 INHIBITORS: Up to 2 mg orally once a day immediately prior to bedtime

  • Maximum dose: 2 mg/day

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to the active component or to any of the ingredients
  • Patients who have previously experienced an episode of complex sleep behaviors after taking this drug

US BOXED WARNINGS:
COMPLEX SLEEP BEHAVIORS:
  • Complex sleep behaviors including sleepwalking, sleep-driving, and engaging in other activities while not fully awake may occur following the use of this drug.
  • Some of these events may result in serious injuries, including death.
Recommendation:
  • Discontinue this drug immediately is a patient experiences a complex sleep behavior.

Safety and efficacy have not been established in pediatric patients.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule IV

Dialysis

Data not available

Other Comments

Administration advice:

  • Doses should be administered immediately before bedtime.
  • The effects of eszopiclone on sleep onset may be reduced if it is taken with or immediately after a high-fat/heavy meal.

General:
  • This drug decreased sleep latency and improved sleep maintenance when administered at bedtime in clinical trials.
  • Taking a sedative/hypnotic while still up and about may result in short-term memory impairment, hallucinations, impaired coordination, dizziness, and lightheadedness.
  • The risk of next day impairment of driving and other activities that require full alertness is increased following use of 2 mg or 3 mg doses.
  • Withdrawal effects may occur if the dose is rapidly reduced or treatment discontinued.

Monitoring:
  • NERVOUS SYSTEM: Changes in cognitive function, including complex behaviors
  • PSYCHIATRIC: New/worsening depression

Patient advice:
  • Patients should be instructed to immediately report "sleep driving," other complex behaviors, and any new/worsening signs/symptoms of depression.
  • Inform patients that this drug may cause somnolence and/or transient amnesia, and they should remain in bed and avoid driving or operating machinery for a full 7 to 8 hours after administration of this drug.
  • Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

Frequently asked questions

  • Is “Ambien-Tweeting” a Thing?
Share this Article
Latest News
Medical News

Gastrointestinal cancer: Can eating chicken shorten lifespan?

May 12, 2025
Shingles vaccine may lower heart disease risk by up to 8 years
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by